Biogen Inc (NASDAQ:BIIB) – Equities research analysts at Leerink Swann reduced their Q1 2017 earnings per share estimates for Biogen in a report issued on Thursday. Leerink Swann analyst G. Porges now anticipates that the brokerage will post earnings of $4.65 per share for the quarter, down from their prior estimate of $4.70. Leerink Swann has a “Market Perform” rating and a $300.00 price objective on the stock. Leerink Swann also issued estimates for Biogen’s Q2 2017 earnings at $5.20 EPS, Q3 2017 earnings at $5.48 EPS, Q4 2017 earnings at $5.52 EPS, FY2017 earnings at $20.85 EPS, FY2018 earnings at $22.97 EPS, FY2019 earnings at $23.93 EPS and FY2021 earnings at $24.44 EPS.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Thursday, January 26th. The biotechnology company reported $5.04 earnings per share for the quarter, beating the consensus estimate of $4.96 by $0.08. Biogen had a net margin of 32.34% and a return on equity of 38.48%. The business had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.94 billion. During the same quarter in the previous year, the firm earned $4.50 earnings per share. The company’s revenue for the quarter was up 1.2% on a year-over-year basis.
Your IP Address:
BIIB has been the topic of several other research reports. Mizuho restated a “sell” rating on shares of Biogen in a report on Monday, February 6th. Vetr downgraded shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $295.39 price objective on the stock. in a report on Tuesday, February 7th. BMO Capital Markets restated a “market perform” rating and set a $294.00 price objective on shares of Biogen in a report on Saturday, November 26th. Raymond James Financial, Inc. upped their price objective on shares of Biogen from $375.00 to $386.00 and gave the company a “strong-buy” rating in a report on Thursday, December 29th. Finally, Jefferies Group LLC restated a “hold” rating and set a $312.00 price objective on shares of Biogen in a report on Sunday, January 8th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. Biogen currently has an average rating of “Buy” and an average price target of $327.74.
Biogen (NASDAQ:BIIB) opened at 274.80 on Monday. The firm’s 50-day moving average is $283.74 and its 200 day moving average is $293.74. The stock has a market cap of $59.34 billion, a P/E ratio of 16.23 and a beta of 0.72. Biogen has a one year low of $223.02 and a one year high of $333.65.
Several large investors have recently modified their holdings of BIIB. Capital Analysts LLC boosted its stake in shares of Biogen by 1.4% in the fourth quarter. Capital Analysts LLC now owns 423 shares of the biotechnology company’s stock worth $120,000 after buying an additional 6 shares during the last quarter. Bienville Capital Management LLC boosted its stake in shares of Biogen by 0.7% in the fourth quarter. Bienville Capital Management LLC now owns 861 shares of the biotechnology company’s stock worth $244,000 after buying an additional 6 shares during the last quarter. Reilly Financial Advisors LLC boosted its stake in shares of Biogen by 0.9% in the third quarter. Reilly Financial Advisors LLC now owns 915 shares of the biotechnology company’s stock worth $286,000 after buying an additional 8 shares during the last quarter. Intrust Bank NA boosted its stake in shares of Biogen by 0.5% in the third quarter. Intrust Bank NA now owns 1,794 shares of the biotechnology company’s stock worth $562,000 after buying an additional 9 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC boosted its stake in shares of Biogen by 3.0% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 408 shares of the biotechnology company’s stock worth $116,000 after buying an additional 12 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.
In other news, CEO Michel Vounatsos acquired 1,333 shares of the company’s stock in a transaction dated Monday, February 27th. The shares were acquired at an average price of $285.39 per share, with a total value of $380,424.87. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Robert W. Pangia sold 5,450 shares of the firm’s stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $295.39, for a total transaction of $1,609,875.50. Following the sale, the director now directly owns 22,078 shares in the company, valued at approximately $6,521,620.42. The disclosure for this sale can be found here. 0.32% of the stock is currently owned by corporate insiders.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.